<DOC>
	<DOCNO>NCT00709163</DOCNO>
	<brief_summary>Nesiritide rapid vasodilator mimic action endogenous hormone - human B-type natriuretic peptide ( BNP ) . BNP produce naturally ventricles heart response stretch . Nesiritide decrease systemic vascular resistance ( SVR ) , pulmonary capillary wedge pressure ( PCWP ) , right atrial pressure ( RAP ) , mean pulmonary arterial pressure . Nesiritide affect heart rate , increase stroke volume consequently cardiac output , result decrease symptom decompensated heart failure . It generally well tolerate , major negative side effect hypotension . When compare standard therapy consist dobutamine nitroglycerin , nesiritide similar vasodilatory effect , show low incidence arrhythmia . Nesiritide approve IV treatment patient acutely decompensated congestive heart failure . Although study test effectiveness safety nesiritide adult CHF patient , do child . Subjects enrol study pediatric ( &lt; 21 year ) patient carry diagnosis dilate cardiomyopathy decompensated congestive heart failure . The standard care patient undergo cardiac catheterization placement Swan-Ganz catheter hemodynamic monitoring . Subjects randomly assign receive either Nesiritide placebo ( 5 % Dextrose ) . The infusion continue total twenty-four hour . During one day period , measurement systemic blood pressure , central venous pressure ( right atrial pressure ) , pulmonary capillary wedge pressure , cardiac output , mixed venous saturation , pulmonary vascular resistance , systemic vascular resistance measure regularly schedule interval . The Swan-Ganz catheter remain place 2 hour discontinuation study drug , remove . The objective study : 1 . To assess efficacy Nesiritide therapy decrease pulmonary capillary wedge pressure , right atrial pressure , systemic vascular resistance child dilate cardiomyopathy . 2 . To assess efficacy Nesiritide decrease pulmonary edema increase cardiac index mention population . 3 . To assess safety bolus administration continuous infusion Nesiritide child dilate cardiomyopathy . 4 . To assess pharmacokinetics Nesiritide population .</brief_summary>
	<brief_title>Nesiritide - Dilated Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>1 . Diagnosis dilate cardiomyopathy 2 . Less 21 year age 3 . Patient admit intensive care unit 4 . Patient require placement SwanGanz catheter 5 . Patient 's hemodynamics clinical condition require use SwanGanz catheter 26 hour follow cardiac catheterization . 6 . Patient sign IRB approve consent form . 1 . Severe hemodynamic instability include patient require ECMO 2 . Cardiac catheterization indicate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Dilated Cardiomyopathy</keyword>
	<keyword>Nesiritide</keyword>
</DOC>